EUVIMEDEUVIMED entdecken
Open Access

Expression and Diagnostic Significance of Clinical Routine VMAT2 Immunostaining in Neuroendocrine Neoplasia: A Study of Institutional Cases

Zandra Ankers iD, L Samuel Hellgren iD, C Christofer Juhlin iD

Journal of Histochemistry & Cytochemistry · 2026

DOI: 10.1369/00221554261424958 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Histochemistry & Cytochemistry, 2026. Verfasst von Zandra Ankers und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Vesicular Monoamine Transport Proteins, Neuroendocrine Tumors, Biomarkers, Tumor. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancerfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vesicular monoamine transporter 2 (VMAT2) is an integral membrane protein that packages monoamines, including dopamine, norepinephrine, serotonin, and histamine, into synaptic vesicles. VMAT2 is normally expressed in sympathetic, enteric, and central nervous system neurons and in neuroendocrine cells. Although VMAT2 immunoreactivity was originally reported in a wide range of neuroendocrine neoplasms (NENs), its diagnostic value has been largely overlooked in recent practice due to reliance on established markers such as chromogranin A (CgA), synaptophysin (SYP), and the transcription factors ISLET1 and INSM1. To reassess the relevance of VMAT2, we evaluated its expression relative to CgA, SYP, ISLET1, and INSM1 in 60 consecutively diagnosed NENs from diverse anatomic sites and tumor grades. VMAT2 was positive in 37 of 39 (95%) well-differentiated neuroendocrine tumors (NETs; grades 1–3), in all adrenal paragangliomas (7 of 7) and in one medullary thyroid carcinoma, showing sensitivity comparable to CgA and INSM1 and slightly lower than SYP. VMAT2 was detected in 7 of 12 (58%) neuroendocrine carcinomas. Sensitivity was highest in small-intestinal and gastric NETs and more variable in pancreatic NETs. These results support VMAT2 as a robust, differentiation-linked neuroendocrine marker whose inclusion in modern immunohistochemical panels may improve diagnostic accuracy:

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vesicular Monoamine Transport ProteinsNeuroendocrine TumorsBiomarkers, TumorHumansFemaleImmunohistochemistryMaleSynaptophysinMiddle AgedAgedAdultChromogranin ARepressor Proteins

Stichwörter der Autor:innen

VMAT2neuroendocrine carcinomaneuroendocrine neoplasianeuroendocrine tumor

Substanzen

Vesicular Monoamine Transport ProteinsSLC18A2 protein, humanBiomarkers, TumorSynaptophysinChromogranin AINSM1 protein, humanRepressor Proteins

Autor:innen und Institutionen

  • Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden.

ORCID-Profile: Zandra Ankers, L Samuel Hellgren, C Christofer Juhlin

Förderung

  • Cancerfonden

Zitieren

APA

Ankers, Z., Hellgren, L. S., & Juhlin, C. C. (2026). Expression and Diagnostic Significance of Clinical Routine VMAT2 Immunostaining in Neuroendocrine Neoplasia: A Study of Institutional Cases. Journal of Histochemistry & Cytochemistry. https://doi.org/10.1369/00221554261424958

Vancouver

Ankers Z, Hellgren LS, Juhlin CC. Expression and Diagnostic Significance of Clinical Routine VMAT2 Immunostaining in Neuroendocrine Neoplasia: A Study of Institutional Cases. Journal of Histochemistry & Cytochemistry. 2026. doi:10.1369/00221554261424958

BibTeX
@article{Ankers2026,
  author = {Ankers, Zandra and Hellgren, L Samuel and Juhlin, C Christofer},
  title = {Expression and Diagnostic Significance of Clinical Routine VMAT2 Immunostaining in Neuroendocrine Neoplasia: A Study of Institutional Cases},
  journal = {Journal of Histochemistry & Cytochemistry},
  year = {2026},
  doi = {10.1369/00221554261424958}
}
Kostenlos starten →